Applications of Di-Tert-Butyl Azodicarboxylate in Industrial Manufacturing

Our Di-Tert-Butyl Azodicarboxylate is formulated for reliable integration within specialized synthesis and transformation processes. Below, we detail its primary downstream applications in concentrated industrial segments, highlighting formulation practices, technical roles in workflows, applicable regulatory frameworks, and real final product categories as required by international buyers and partners.

1. Fine Chemical Synthesis: Mitsunobu Reaction Reagents

In fine chemical manufacture, this compound acts as a specialized azo coupling and oxidizing agent within Mitsunobu reactions, supporting alcohol activation and facilitating phosphine-azodicarboxylate pairings that drive efficient nucleophilic substitutions. Formulators add it immediately prior to substrate transformation to minimize degradation, enabling production of functionalized intermediates for further downstream elaboration in custom molecule pipelines.

Industry compliance standards

• REACH Regulation (EC) No. 1907/2006
• ISO 9001:2015 Quality Management
• cGMP for Fine Chemical Production where required by customer
• OECD Good Laboratory Practice (GLP) guidelines (for intermediates in regulated programs)

Typical usage ratio

• 0.9–1.3 molar equivalents relative to alcohol or substrate; variation based on substrate reactivity and desired conversion rate

Downstream process integration

• Added as an active reagent directly to the substrate-phosphine mixture at controlled temperatures (0–25°C); consumed during formation of hydrazine byproducts; downstream product extracted post-oxidation step

Final product types

• Alcohol-derived esters, ethers, and amines for active pharmaceutical ingredient (API) intermediates
• Functional fragrance or agrochemical intermediates
• Specialty material building blocks
• Protected amino acid derivatives for peptide synthesis

2. Pharmaceutical API Intermediate Manufacturing

As an azodicarboxylate type oxidant, this material supports regioselective transformations in multi-step API synthesis, specifically for generating protected hydrazines or as a facilitating reagent for nucleophilic substitution in chiral centers. Production plants use it within batch and continuous reactor systems calibrated for sensitive pharma intermediate controls, as reliable removal after reaction allows for high-purity end-stage intermediates required by stringent health agency submissions.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• US FDA 21 CFR Part 210/211 (for U.S. supply)
• EU EudraLex Volume 4 GMP Guidelines
• Ph. Eur., USP, and JP Residual Reagent Limit specifications

Typical usage ratio

• 0.8–1.2 molar equivalents per functional group underwent modification; closely adjusted per validated synthesis route and scale

Downstream process integration

• Charged in closed reactor vessels following the complete dissolution of substrates; reacted under inert nitrogen or argon; removed post reaction by solvent partition or crystallization, minimizing carryover into subsequent purification steps

Final product types

• Hydrazine-protected pharmaceutical key intermediates
• Chiral amine intermediates for central nervous system (CNS) APIs
• Advanced intermediates for oncology and antiviral agents
• High-purity building blocks for commercial API manufacturing

3. Agrochemical Intermediate Synthesis

This product plays a critical role in the development of crop protection intermediates, especially for selective N-alkylation or esterification in the preparation of pyrazole, pyridine, and other heterocyclic scaffolds. Agrochemical formulators apply it within controlled synthesis steps involving base-promoted or transition metal-catalyzed conditions, allowing tight process management of reaction kinetics and byproduct formation to meet residue and purity specifications for regulatory submissions.

Industry compliance standards

• ISO 9001:2015 Quality Management for Agrochemical Precursors
• European Regulation (EC) No 1107/2009 (Plant Protection Products)
• FAO and WHO Guidelines for Technical Specifications (where applicable)
• EPA Environmental Protection Agency Risk Assessment Guidelines

Typical usage ratio

• 1.0–1.5 equivalents per nucleophile, subject to substrate load and downstream process yield optimization

Downstream process integration

• Pumped into reactors after heterocycle formation; engages directly with precursor in the presence of basic catalysts; removed post-reaction via liquid–liquid extraction and filtration before finishing steps

Final product types

• Intermediates for fungicides and insecticide active ingredients
• Protected amines for selective herbicide backbones
• Building blocks for formulation-grade agrochemicals
• Key intermediates for biopesticide raw materials

4. Peptide and Oligonucleotide Synthesis

This azodicarboxylate finds specialized use in solid-phase and solution-phase peptide and oligonucleotide assembly, where it acts as an auxiliary reagent for Mitsunobu-based protection and temporary modification of amino acids and nucleosides. SOPs specify its introduction at strictly defined stages to maximize coupling efficiency and to secure orthogonally-protected species important for downstream chain elongation, minimizing base cleavage risks and racemization during final deprotection steps.

Industry compliance standards

• USP <1047> Good Manufacturing Practices for Bulk Peptide Chemicals
• Ph. Eur. 2034: Peptide Active Substances
• ISO 13485:2016 Medical Device Quality Management (for diagnostic oligonucleotides)
• ICH Q3A/B Residual Solvents and Impurities Guidelines

Typical usage ratio

• 0.95–1.1 equivalents per coupling cycle, optimized per amino acid or nucleoside modification; adjusted for resin loading or scale factors

Downstream process integration

• Dosed immediately prior to each coupling or protection cycle under strictly anhydrous conditions; reacts with primary hydroxy or amine groups; eliminated before cleavage from solid support or after solution-phase work-up

Final product types

• Synthetic peptides for research and diagnostic use
• API-grade peptide precursors
• Pharmaceutical-grade oligonucleotides
• Custom sequence diagnostic kits